arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Prelude Therapeutics Incorporated

PRLD Health Care Biotechnology: Pharmaceutical Preparations
$5.46
Today
as of Sep 4, 16:53 ET
Last 30 days +40.36% Jul 27 → Sep 04
$3.67 $4.47 $5.26 $6.05 $6.85 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$5.19
High
$5.52
Low
$5.19
Volume
$400,284
Avg Vol
$666,620
Mkt Cap
$519M
P/E (TTM)
—
Beta
—
52w High
$6.83
52w Low
$0.98
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 3 items

Aug 11 · 11:00 PR GlobeNewswire
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jul 31 · 13:55 Zacks
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
Jul 17 · 16:00 Zacks
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

Overview

52-week range
$0.98
$6.83
77% of range
Avg surprise (last 3)
+23.8%
Avg reaction (last 2)
-3.2%
0% positive
Latest IV / EM
158%
EM ±24.7% · $5 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.58$-0.47$-0.35$-0.24$-0.13 Actual $-0.58Actual $-0.54Actual $-0.45Actual $-0.42Actual $-0.46Actual $-0.43Actual $-0.42Est $-0.47Actual $-0.41Est $-0.45Actual $-0.26Actual $-0.13Est $-0.27Actual $-0.14 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-32M$-22M$-13M$-3M$7M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.14 — — — — financials
Tue May 12, 2026Mar/2026 $-0.13 $-0.27 +51.9% +69.0% -3.3% earnings
Tue Sep 30, 2025Sep 2025 $-0.26 — — — — financials
Thu Aug 14, 2025Jun/2025 $-0.41 $-0.45 +8.9% — — earnings
Tue May 6, 2025Mar/2025 $-0.42 $-0.47 +10.6% — -3.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.43 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.46 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.42 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.45 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.54 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.58 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$6M$5M—$6M$0$0—$3M
Cost of revenue————————
Gross profit————————
Operating income$-15M$-14M—$-20M$-32M$-35M—$-34M
Net income$-14M$-10M—$-20M$-31M$-32M—$-32M
EPS (diluted)$-0.14$-0.13—$-0.26$-0.41$-0.42—$-0.43

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$26M$22M$35M$48M$26M$40M$12M$11M
Inventory————————
Total current assets$155M$85M$106M$58M$77M$102M$136M$156M
Total assets$189M$120M$141M$95M$115M$141M$176M$197M
Long-term debt————————
Total liabilities$56M$59M$73M$36M$39M$38M$44M$41M
Total equity$134M$60M$69M$59M$76M$103M$131M$156M

Implied volatility — last 90 days

113%313%512%712%912% Jun 07 — IV 284% · EM ±39.4%Jun 08 — IV 291% · EM ±38.4%Jun 09 — IV 506% · EM ±63.5%Jun 10 — IV 305% · EM ±36.1%Jun 11 — IV 528% · EM ±58.4%Jun 12 — IV 272% · EM ±27.8%Jun 15 — IV 287% · EM ±20.7%Jun 16 — IV 645% · EM ±38.1%Jun 17 — IV 881% · EM ±36.8%Jun 19 — IV 199% · EM ±44.0%Jun 22 — IV 244% · EM ±50.9%Jun 23 — IV 234% · EM ±47.9%Jun 24 — IV 175% · EM ±35.1%Jun 25 — IV 249% · EM ±48.8%Jun 26 — IV 200% · EM ±38.2%Jun 29 — IV 140% · EM ±24.8%Jun 30 — IV 120% · EM ±20.7%Jul 01 — IV 146% · EM ±24.4%Jul 02 — IV 164% · EM ±26.5%Jul 03 — IV 169% · EM ±26.5%Jul 06 — IV 134% · EM ±18.5%Jul 07 — IV 202% · EM ±26.7%Jul 08 — IV 203% · EM ±25.4%Jul 09 — IV 177% · EM ±20.9%Jul 10 — IV 259% · EM ±28.6%Jul 13 — IV 324% · EM ±27.0%Jul 14 — IV 441% · EM ±31.9%Jul 15 — IV 484% · EM ±28.6%Jul 16 — IV 912% · EM ±38.1%Jul 20 — IV 302% · EM ±71.4%Jul 21 — IV 194% · EM ±45.2%Jul 22 — IV 691% · EM ±158.1%Jul 23 — IV 239% · EM ±53.8%Jul 24 — IV 331% · EM ±73.1%Jul 27 — IV 332% · EM ±69.4%Jul 28 — IV 147% · EM ±30.1%Jul 29 — IV 143% · EM ±28.7%Jul 30 — IV 152% · EM ±29.7%Jul 31 — IV 142% · EM ±27.2%Aug 03 — IV 174% · EM ±30.8%Aug 04 — IV 225% · EM ±38.7%Aug 05 — IV 188% · EM ±31.4%Aug 06 — IV 155% · EM ±25.1%Aug 07 — IV 140% · EM ±21.9%Aug 10 — IV 157% · EM ±21.8%Aug 11 — IV 169% · EM ±22.4%Aug 12 — IV 181% · EM ±22.7%Aug 13 — IV 150% · EM ±17.7%Aug 14 — IV 171% · EM ±18.9%Aug 17 — IV 175% · EM ±14.7%Aug 18 — IV 373% · EM ±27.0%Aug 19 — IV 527% · EM ±31.1%Aug 20 — IV 847% · EM ±35.4%Aug 24 — IV 167% · EM ±34.8%Aug 25 — IV 161% · EM ±33.0%Aug 26 — IV 166% · EM ±33.2%Aug 27 — IV 159% · EM ±31.2%Aug 28 — IV 136% · EM ±26.1%Aug 31 — IV 113% · EM ±20.1%Sep 01 — IV 138% · EM ±23.7%Sep 02 — IV 215% · EM ±35.9%Sep 03 — IV 215% · EM ±34.8%Sep 04 — IV 158% · EM ±24.7%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in